Inovio to present additional prostate cancer data at ASCO
Inovio Pharmaceuticals announced a poster presentation of additional prostate cancer data at the American Society of Clinical Oncology, or ASCO, annual meeting to be held in Chicago, June 1-5, 2018. Previously reported data from a Phase 1b clinical trial demonstrated that Inovio's cancer immunotherapy slowed PSA rise in patients with biochemically recurrent prostate cancer. Additional analyses show clinically meaningful PSA stabilization post-administration of Inovio's immunotherapy in patients with no documented disease progression during the study. Of note, this effect was also observed in the patients with the fastest PSA doubling at the time of study entry. The multi-center Phase 1b study enrolled 62 patients with biochemically relapsed prostate cancer following definitive local therapy. Under the trial design, eligible patients received INO-5150, DNA plasmids encoding prostate specific antigen, or PSA, and prostate specific membrane antigen, or PSMA, alone or co-administered with INO-9012 delivered intramuscularly followed by EP using the CELLECTRA-5P device. Of the 61 evaluable patients, 77% demonstrated T cell immunogenicity, and 38% exhibited CD38+, Perforin+CD8+ T cell responses. Additional analyses are underway to elucidate the correlation between immunologic efficacy and clinical benefit.